TRCT
OLMA icon

Tower Research Capital (TRC)’s Olema Pharmaceuticals OLMA Stock Holding History

Tower Research Capital (TRC)’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.4K Sell
2,347
-3,705
-61% -$49.6K ﹤0.01% 3194
2026
Q1 		$90.2K Sell
6,052
-3,886
-39% -$86.5K ﹤0.01% 2265
2025
Q4 		$248K Buy
9,938
+7,413
+294% +$132K 0.01% 1270
2025
Q3 		$24.7K Sell
2,525
-5,479
-68% -$32.9K ﹤0.01% 3111
2025
Q2 		$34.1K Buy
8,004
+2,610
+48% +$11.6K ﹤0.01% 3306
2025
Q1 		$20.3K Sell
5,394
-17,320
-76% -$87.1K ﹤0.01% 2951
2024
Q4 		$132K Buy
22,714
+21,236
+1,437% +$212K ﹤0.01% 1991
2024
Q3 		$17.6K Sell
1,478
-7,722
-84% -$98.7K ﹤0.01% 3306
2024
Q2 		$99.5K Buy
9,200
+7,584
+469% +$82.2K ﹤0.01% 2583
2024
Q1 		$18.3K Sell
1,616
-8,906
-85% -$115K ﹤0.01% 3075
2023
Q4 		$148K Buy
10,522
+9,370
+813% +$126K ﹤0.01% 2332
2023
Q3 		$14.2K Sell
1,152
-20
-2% -$204 ﹤0.01% 3703
2023
Q2 		$10.6K Sell
1,172
-27,978
-96% -$169K ﹤0.01% 4099
2023
Q1 		$101K Buy
29,150
+19,358
+198% +$79K ﹤0.01% 1862
2022
Q4 		$24K Buy
9,792
+2,414
+33% +$7.04K ﹤0.01% 2966
2022
Q3 		$20K Sell
7,378
-748
-9% -$3.17K ﹤0.01% 3939
2022
Q2 		$33K Buy
8,126
+2,170
+36% +$6.88K ﹤0.01% 3280
2022
Q1 		$25K Sell
5,956
-915
-13% -$5.04K ﹤0.01% 3330
2021
Q4 		$64K Buy
6,871
+6,542
+1,988% +$136K ﹤0.01% 2571
2021
Q3 		$9K Sell
329
-900
-73% -$24.3K ﹤0.01% 4458
2021
Q2 		$34K Buy
1,229
+61
+5% +$1.74K ﹤0.01% 3353
2021
Q1 		$39K Buy
1,168
+598
+105% +$25.6K ﹤0.01% 3334
2020
Q4 		$27K Buy
+570
New +$26.7K ﹤0.01% 3663

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Tower Research Capital (TRC)'s OLMA Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Olema Pharmaceuticals (OLMA) stake by 61% in Q2 2026, selling an estimated $49.6K and leaving 2,347 shares worth $29.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

Tower Research Capital (TRC) first reported a position in OLMA in Q4 2020 and has held it in 23 quarters since. The position peaked at $248K in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Tower Research Capital (TRC) held 2,347 shares of Olema Pharmaceuticals worth $29.4K as of Q2 2026.
  • Tower Research Capital (TRC) sold 3,705 Olema Pharmaceuticals shares in Q2 2026, an estimated $49.6K.
  • Olema Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3194 holding.
  • Tower Research Capital (TRC) first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Olema Pharmaceuticals position peaked at $248K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.